Stockscreener 앱 받기
8.05
4.14%
0.32
시간 외 거래:
8.01
-0.04
-0.50%
CorMedix Inc 주식(CRMD)의 최신 뉴스
What CorMedix says before the bell May 14: earnings and update - Stock Titan
CorMedix Therapeutics to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 14, 2026 - Yahoo Finance
CorMedix stock falls 5% on fourth quarter earnings miss - Investing.com
Cormedix Stock Pre-Market (+6.2%) : Technical Move Ahead of Key Q2 Catalyst - Trefis
CorMedix reports Q4 revenue of $128.6M, reaffirms 2026 guidance - Investing.com
CorMedix banks on DefenCath sales in Q4 as Melinta adds upside - MSN
CRMD News | CORMEDIX INC (NASDAQ:CRMD) - ChartMill
HC Wainwright & Co. Maintains CorMedix (CRMD) Buy Recommendation - MSN
[ARS] CorMedix Inc. SEC Filing - Stock Titan
CorMedix (CRMD) posts 2025 profit, seeks approval of key charter and governance changes - Stock Titan
CorMedix | 4: Statement of changes in beneficial ownership of securities-Officer Hurlburt Elizabeth - Moomoo
H.C. Wainwright reiterates CorMedix stock rating on trial results By Investing.com - Investing.com India
Truist Financial Maintains CorMedix(CRMD.US) With Buy Rating - Moomoo
CorMedix stock rating maintained at outperform by Citizens By Investing.com - Investing.com India
A Quick Look at Today's Ratings for CorMedix(CRMD.US), With a Forecast Between $13 to $15 - Moomoo
H.C. Wainwright reiterates CorMedix stock rating on trial results - Investing.com UK
H.C. Wainwright Maintains CorMedix(CRMD.US) With Buy Rating, Maintains Target Price $13 - Moomoo
RBC Raises Price Target on CorMedix to $14 From $13, Keeps Outperform, Speculative Risk - marketscreener.com
CorMedix stock rating maintained at outperform by Citizens - Investing.com Australia
symbol__ Stock Quote Price and Forecast - CNN
Positive REZZAYO Phase III Prophylaxis Data Might Change The Case For Investing In CorMedix (CRMD) - Sahm
Cormedix Stock Soars Pre-Market After Earnings Beat, Higher Full-Year Guidance - MSN
Needham Maintains CorMedix(CRMD.US) With Buy Rating, Raises Target Price to $15 - Moomoo
CorMedix reports positive Phase III results for rezafungin trial - Investing.com UK
RBC Capital raises CorMedix stock price target on phase III data - Investing.com UK
RBC Capital raises CorMedix stock price target on phase III data By Investing.com - Investing.com South Africa
CorMedix files to sell 6.32M shares of common stock for holders - MSN
CorMedix nears an 11-month low after earnings miss - MSN
CorMedix Eyes $2 Billion Market With Encouraging Data From Fungal Infection Study - Benzinga
CorMedix Announces Positive Phase III Results for Rezafungin in Preventing Invasive Fungal Diseases in Stem Cell Transplant Patients - Minichart
Cormedix Therapeutics announces positive topline results from phase III Respect trial - marketscreener.com
Cormedix Therapeutics Announces Positive Topline Results From Phase Iii Respect Trial - TradingView
CorMedix reports positive Phase III results for rezafungin trial By Investing.com - Investing.com South Africa
Phase III ReSPECT success boosts CorMedix (CRMD) REZZAYO prophylaxis plans - Stock Titan
CorMedix Therapeutics Announces Positive Topline Results from Phase III ReSPECT Trial Assessing REZZAYO® for the Prophylaxis of Invasive Fungal Diseases in Allogeneic Hematopoietic Stem Cell Transplantation Patients - ChartMill
CorMedix shares slip after unveiling lower revenue outlook for 2026 - MSN
(CRMD) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Do options traders know something about CorMedix stock we don't? - MSN
CRMD Stock Price, Quote & Chart | CORMEDIX INC (NASDAQ:CRMD) - ChartMill
1.77%
0.25%
자본화:
|
볼륨(24시간):